Ignite Creation Date:
2025-12-24 @ 11:29 PM
Ignite Modification Date:
2026-01-01 @ 2:49 PM
Study NCT ID:
NCT01755156
Status:
COMPLETED
Last Update Posted:
2018-09-10
First Post:
2012-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-01-11
Start Date Type:
ACTUAL
Primary Completion Date:
2016-03-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-03-16
Completion Date Type:
ACTUAL
First Submit Date:
2012-12-18
First Submit QC Date:
None
Study First Post Date:
2012-12-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-01-30
Results First Submit QC Date:
None
Results First Post Date:
2017-03-20
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-08-09
Last Update Post Date:
2018-09-10
Last Update Post Date Type:
ACTUAL